{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:15:18Z","timestamp":1792084518044,"version":"4.4.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-06-72"],"award-info":[{"award-number":["320.6750.2023-06-72"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to evaluate the hematological safety of generic linezolid, providing data to support its rational and safe use in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected from electronic medical records at a tertiary hospital in China between January 2019 and June 2023. We conducted a real-world, retrospective matched cohort study involving hospitalized patients treated with either generic or brand-name linezolid for bacterial infections. Propensity score matching was employed to control for potential risk factors associated with thrombocytopenia. The primary outcome was the incidence of thrombocytopenia adverse events. Secondary outcomes included rates of severe thrombocytopenia, the incidence of anemia meeting transfusion thresholds, and changes in platelet counts (PLTs) and hemoglobin (Hb) levels during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 218 patients received generic linezolid, while 222 patients received the brand-name version. After adjustment, each group had 137 patients. There were no significant differences in thrombocytopenia (28.44% vs. 21.17%), severe thrombocytopenia (6.42% vs. 4.95%), or anemia rates (2.75% vs. 3.15%) (P &amp;gt; 0.05). Similarly, reductions in PLT and HB levels during follow-up did not differ significantly (P &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate no significant differences in the incidence of thrombocytopenia and severe anemia between generic and brand-name linezolid, highlighting the need for further validation in other generic formulations and diverse patient populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1528633","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:45Z","timestamp":1750225305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhizhou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"Doc12","DOI":"10.3205\/dgkh000232","article-title":"Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients","volume":"9","author":"Akhi","year":"2014","journal-title":"GMS Hyg. Infect. Control"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40121-022-00663-3","article-title":"Linezolid vs vancomycin in induced thrombocytopenia","volume":"11","author":"Al-Harbi","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/cpdd.964","article-title":"Pharmacokinetics and bioequivalence study of a new branded generic moxifloxacin tablet among healthy volunteers","volume":"10","author":"Amran","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00134-023-07225-2","article-title":"Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)","volume":"49","author":"Anthon","year":"2023","journal-title":"Intensive Care Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2019-0247","article-title":"In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method","volume":"30","author":"Avianto","year":"2020","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"ofac669","DOI":"10.1093\/ofid\/ofac669","article-title":"Safety profile of linezolid in older adults with renal impairment: a population-based retrospective cohort study","volume":"9","author":"Bai","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1093\/jac\/dkac285","article-title":"Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin\/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers","volume":"77","author":"Bergmann","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bjh.19230","article-title":"Immune thrombocytopenia (ITP) in pregnancy","volume":"204","author":"Bussel","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD002042","DOI":"10.1002\/14651858.CD002042.pub5","article-title":"Transfusion thresholds for guiding red blood cell transfusion","volume":"12","author":"Carson","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10096-019-03754-1","article-title":"Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients","volume":"39","author":"Cazavet","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","article-title":"Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy","volume":"73","author":"Chen","year":"2012","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","article-title":"Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients","volume":"33","author":"Dong","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/antibiotics10010062","article-title":"Real-world use of generic meropenem: results of an observational study","volume":"10","author":"Garnica-Velandia","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10096-017-2960-5","article-title":"Predictive score of haematological toxicity in patients treated with linezolid","volume":"36","author":"Gonz\u00e1lez-Del Castillo","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2147\/DDDT.S189524","article-title":"In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia","volume":"13","author":"Hambisa","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11096-021-01342-y","article-title":"Risk factors for linezolid-induced thrombocytopenia in adult inpatients","volume":"44","author":"Han","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/CNQ.0000000000000440","article-title":"Hematologic and oncologic emergencies","volume":"46","author":"Holden","year":"2023","journal-title":"Crit. Care Nurs. Q."},{"key":"B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11096-024-01810-1","article-title":"Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study","volume":"47","author":"Inoue","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00228-023-03455-x","article-title":"Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia","volume":"79","author":"Inoue","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107109","DOI":"10.1016\/j.ijid.2024.107109","article-title":"Comparative effectiveness and safety of six antibiotics in treating MRSA infections: a network meta-analysis","volume":"146","author":"Ju","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12185-023-03542-w","article-title":"Progress in pathophysiological understanding and treatment of thrombocytopenia","volume":"117","author":"Kashiwagi","year":"2023","journal-title":"Int. J. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1120009X.2022.2043538","article-title":"Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia","volume":"34","author":"Komatsu","year":"2022","journal-title":"J. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/trf.12943","article-title":"Platelet transfusion: a systematic review of the clinical evidence","volume":"55","author":"Kumar","year":"2015","journal-title":"Transfusion"},{"key":"B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone antibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front. Public Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/pds.4122","article-title":"Comparative analysis of the cost and effectiveness of generic and brand-name antibiotics: the case of uncomplicated urinary tract infection","volume":"26","author":"Lin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5414\/CP203986","article-title":"Bioequivalence of cefalexin in healthy Chinese subjects","volume":"59","author":"Lv","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20420986241279128","DOI":"10.1177\/20420986241279128","article-title":"Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study","volume":"15","author":"Ma","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2018.09.011","article-title":"Results of the effectiveness of two piperacillin-tazobactam molecules in the real world","volume":"76","author":"Machado-Alba","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/CPAA.S106676","article-title":"A prospective, observational study comparing the PK\/PD relationships of generic Meropenem (Mercide(\u00ae)) to the innovator brand in critically ill patients","volume":"8","author":"Mer","year":"2016","journal-title":"Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/jac\/dkae155","article-title":"The comparison of the quality of selected brands of antibiotics in Tanzania sourced from different geographical regions","volume":"79","author":"Mwalwisi","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2450\/2018.0143-18","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus."},{"key":"B38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jac\/dkr522","article-title":"A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin","volume":"67","author":"Patel","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00003495-200161040-00008","article-title":"Linezolid: a review of its use in the management of serious gram-positive infections","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1515\/jbcpp-2020-0468","article-title":"Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy","volume":"32","author":"Pratama","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/jcpt.13495","article-title":"A risk factor-based predictive model for linezolid-induced anaemia: a 7-year retrospective study","volume":"46","author":"Qin","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/jcm10071530","article-title":"Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management","volume":"10","author":"Scharf","year":"2021","journal-title":"J. Clin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jac\/dkh409","article-title":"Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study","volume":"54","author":"Senneville","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1128\/AAC.00388-15","article-title":"Nephrotoxicity comparison of two commercially available generic vancomycin products","volume":"59","author":"Sutton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3748\/wjg.v24.i13.1386","article-title":"Thrombocytopenia after liver transplantation: should we care","volume":"24","author":"Takahashi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.xphs.2021.02.014","article-title":"Classification tree analysis based on machine learning for predicting linezolid-induced thrombocytopenia","volume":"110","author":"Takahashi","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/antibiotics10050530","article-title":"Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers","volume":"10","author":"Thirot","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B48","unstructured":"National Institute of allergy and infectious diseases DoA. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1\n          \n          \n          2017"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1093\/jac\/dkad276","article-title":"Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects","volume":"78","author":"Veerman","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-020-0338-x","article-title":"The high cost of prescription drugs: causes and solutions","volume":"10","author":"Vincent","year":"2020","journal-title":"Blood Cancer J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J. Infect."},{"key":"B52","doi-asserted-by":"publisher","first-page":"116801","DOI":"10.1016\/j.biopha.2024.116801","article-title":"Contribution of human organic anion transporter 3-mediated transport of a major linezolid metabolite, PNU-142586, in linezolid-induced thrombocytopenia","volume":"175","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1080\/14740338.2024.2309225","article-title":"Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS","volume":"23","author":"Yu","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","article-title":"Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1528633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:41:47Z","timestamp":1750225307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1528633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":55,"alternative-id":["10.3389\/fphar.2025.1528633"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1528633","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1528633"}}